抗凝新药利伐沙班临床研究进展  

Clinical Research on Rivaroxaban,a New Oral Anticoagulant

作　　者：陈怡琳[1] 施仲伟[1] 

机构地区：[1]上海交通大学医学院附属瑞金医院心脏科,上海200025

出　　处：《心血管病学进展》2009年第5期810-813,共4页Advances in Cardiovascular Diseases

摘　　要：现有抗凝药物因出血、频繁监测等原因致使临床使用受限,作为Ⅹa因子直接抑制剂,小分子口服药物利伐沙班具有明确的药代动力学及药效动力学改变,目前正在临床试验阶段,且有望能够取代传统抗凝药物。Current anticoagulants have some limitations such as bleeding and frequent monitoring,which make clinical administration difficult.Rivaroxaban,now undergoing clinical development,is a small-molecule,oral,direct factor Xa inhibitor with predictable pharmacodynamics and pharmacokinetics.It is hoped that rivaroxaban will be a promising alternative to the traditional anticoagulants.

关 键 词：抗凝药物 利伐沙班 Ⅹa因子 

分 类 号：R96[医药卫生—药理学]